Zandu Pharma shoots up on bonus issue plan
Zandu Pharmaceutical Works jumped 10% to Rs 4,644.05, the maximum permissible level, after its board decided to consider a bonus issue.
The stock had witnessed a consolidation over the past few days after a sharp surge last month.The company is one of those few companies having a face value of Rs 100. It is also a very thinly traded share. The average daily volume in the stock on BSE in the past one year, was just 261 shares.
The company’s book value per share was Rs 1,046.30, as on 31 March 2006. The company’s equity base is a tiny Rs 6.05 crore.
Zandu Pharmaceutical manufactures a wide range of ayurvedic products, specialising in rheumatology, gynaecology and central nervous system. At present, the company has more than 300 products in the form of ghritas, medical oils, churna, quath, tablets and pills sold under the company name. The company enjoys a very strong brand presence with products like Zandu Balm, Zandu Pancharishta, Trisun and Zandu Kesri Jivan.
On 30 October, the company reported strong Q2 results. The net profit jumped 67.3% to Rs 5.37 crore (Rs 3.21 crore). Net sales rose 24.5% to Rs 37.24 crore.
Some time back the company kickstarted 'Manthan,' a project to re-look/devise and implement the a strategy for growth by leveraging on brand equity, launching new products, revamping existing ones, strengthening the marketing inputs through advertisement and sales promotion support, enhancing efficacy of the distribution channel, and by entering into untapped markets.
It had also set up a division to cater to vaidyas, Ayurvedic hospitals, and dispensaries.
The stock had witnessed a consolidation over the past few days after a sharp surge last month.The company is one of those few companies having a face value of Rs 100. It is also a very thinly traded share. The average daily volume in the stock on BSE in the past one year, was just 261 shares.
The company’s book value per share was Rs 1,046.30, as on 31 March 2006. The company’s equity base is a tiny Rs 6.05 crore.
Zandu Pharmaceutical manufactures a wide range of ayurvedic products, specialising in rheumatology, gynaecology and central nervous system. At present, the company has more than 300 products in the form of ghritas, medical oils, churna, quath, tablets and pills sold under the company name. The company enjoys a very strong brand presence with products like Zandu Balm, Zandu Pancharishta, Trisun and Zandu Kesri Jivan.
On 30 October, the company reported strong Q2 results. The net profit jumped 67.3% to Rs 5.37 crore (Rs 3.21 crore). Net sales rose 24.5% to Rs 37.24 crore.
Some time back the company kickstarted 'Manthan,' a project to re-look/devise and implement the a strategy for growth by leveraging on brand equity, launching new products, revamping existing ones, strengthening the marketing inputs through advertisement and sales promotion support, enhancing efficacy of the distribution channel, and by entering into untapped markets.
It had also set up a division to cater to vaidyas, Ayurvedic hospitals, and dispensaries.
posted by SY at 4:47 PM
0 Comments:
Post a Comment
<< Home